23 C
New York
Thursday, June 11, 2026

Tag: biopharmaceutical

newssourceFORcompanyinformationcontent1marketreleases

DBV Technologies to Present New Positive Data from VITESSE Study and Preview Recently Initiated THRIVE Study at the EAACI Congress 2026

Châtillon, France, June 8, 2026

Mineralys Therapeutics to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference

RADNOR, Pa., June 08, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS),  a biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, today announced that management will be participating in the Goldman Sachs 47th Annual Global Healthcare Conference being held in Miami on June 8-10, 2026.

Oculis to Present at the 47th Annual Goldman Sachs Global Healthcare Conference

ZUG, Switzerland, June 08, 2026 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company focused on innovations addressing neuro-ophthalmic and ophthalmic diseases with significant unmet medical needs, announced today that Oculis’ management will participate in a fireside chat at the 47th Annual Goldman Sachs Global Healthcare Conference.  

Lennox-Gastaut Syndrome (LGS) Foundation Launches Pre-Competitive Research Accelerator for LGS and Associated Developmental and Epileptic Encephalopathies

SAN DIEGO, June 8, 2026 /PRNewswire/ -- The Lennox-Gastaut Syndrome (LGS) Foundation today announced the launch of the LGS and Associated DEE Research Accelerator,...

Phenomenex Introduces Luna Omega HILIC LC Columns to Increase Sensitivity and Consistency in Polar Compound Analysis

Enhanced Polar Compound Retention and SeparationTORRANCE, Calif., June 8, 2026 /PRNewswire/ -- Phenomenex Inc., a Danaher Company and a global leader in the research...

Phenomenex Introduces Luna Omega HILIC LC Columns to Increase Sensitivity and Consistency in Polar Compound Analysis

Enhanced Polar Compound Retention and SeparationTORRANCE, Calif., June 8, 2026 /PRNewswire/ -- Phenomenex Inc., a Danaher Company and a global leader in the research...

Phenomenex Introduces Luna Omega HILIC LC Columns to Increase Sensitivity and Consistency in Polar Compound Analysis

Enhanced Polar Compound Retention and SeparationTORRANCE, Calif., June 8, 2026 /CNW/ -- Phenomenex Inc., a Danaher Company and a global leader in the research...

Waters Launches Industry-First Reversed-Phase Bioseparation Columns to Deliver Up to 3x Faster GLP-1 Characterization and 2x Faster LNP Component Analysis

Faster run times for GLP-1, insulin, and LNP drug substance testing accelerates biopharmaceutical development timelines and reduces production bottlenecks.Delivers up to 2x increase in...

Foresee’s Oral ALDH2 Activator, Mirivadelgat to Enter Clinical Testing in Parkinson’s Disease in the SLEIPNIR Phase 2a Platform Trial

TAIPEI, June 8, 2026 /PRNewswire/ -- Foresee Pharmaceuticals (6576.TWO), ("Foresee") announced today that Foresee's oral ALDH2 activator, mirivadelgat, has been selected to enter clinical testing in...

GNI Group to Acquire Ayumi Pharmaceutical Holdings, Expanding Its Position as a Global Biopharmaceutical Company

Transaction Establishes a Large-Scale Pharmaceutical Platform in Japan and Strengthens Commercial Capabilities Across Key Therapeutic Areas 
Transaction Establishes a Large-Scale Pharmaceutical Platform in Japan and Strengthens Commercial Capabilities Across Key Therapeutic Areas

LENZ Therapeutics Announces Everest Medicines Acquired Rights to Develop and Commercialize VIZZ® (LNZ100) in Greater China

The New Drug Application for LNZ100 in China was submitted September 2025 with approval anticipated in Q1 2027 
The New Drug Application for LNZ100 in China was submitted September 2025 with approval anticipated in Q1 2027

Zealand Pharma announces Boehringer Ingelheim’s survodutide Phase III trial in people living with obesity showed targeted 34% visceral and 63% liver fat reduction, while...

Company announcement No. 21 / 2026

Head-to-head Study Validates the Clinical Advantage of New-generation Biased GLP-1: Ecnoglutide Delivers 35% Greater Weight Loss than Semaglutide

NEW ORLEANS, June 7, 2026 /PRNewswire/ -- Hangzhou Sciwind Biosciences Co., Ltd. ("Sciwind Biosciences"), a commercial-stage biopharmaceutical company focused on discovering and developing innovative...

Head-to-head Study Validates the Clinical Advantage of New-generation Biased GLP-1: Ecnoglutide Delivers 35% Greater Weight Loss than Semaglutide

NEW ORLEANS, June 8, 2026 /PRNewswire/ -- Hangzhou Sciwind Biosciences Co., Ltd. ("Sciwind Biosciences"), a commercial-stage biopharmaceutical company focused on discovering and developing innovative...

- A word from our sponsors -

spot_img
HomeTagsBiopharmaceutical

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers